Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Journal of the American College of Surgeons|February 21, 2017
Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival OutcomesJohn M Creasy, Debra A Goldman, Vikas Dudeja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancerKenneth H Yu, Mark Ricigliano, Manuel Hidalgo, et al.
Acta Oncologica (Stockholm, Sweden)|June 30, 2017
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancerJoseph J Park, Carla Hajj, Marsha Reyngold, et al.
Clinical Colorectal Cancer|March 3, 2018
Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?Emmet J Jordan, Maeve A Lowery, Olca Basturk, et al.
JCO Precision Oncology|July 12, 2021
Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsAnna M Varghese, Juber Patel, Yelena Y Janjigian, et al.
The Oncologist|September 22, 2011
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directionsMaeve A Lowery, David P Kelsen, Zsofia K Stadler, et al.
Annals of Surgical Oncology|June 13, 2015
FOLFIRINOX Induction Therapy for Stage 3 Pancreatic AdenocarcinomaEran Sadot, Alexandre Doussot, Eileen M O'Reilly, et al.
Investigational New Drugs|April 28, 2019
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsBin Fan, Ingo K Mellinghoff, Patrick Y Wen, et al.
Cancer|February 4, 2020
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findingsHannah Maynard, Zsofia K Stadler, Michael F Berger, et al.
Investigational New Drugs|July 13, 2019
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinomaMarcus Noel, Eileen M O'Reilly, Brian M Wolpin, et al.
Pageof 7